FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112739539> ?p ?o ?g. }

• W3112739539 endingPage "1270" @default.
• W3112739539 startingPage "1263" @default.
• W3112739539 abstract "Purpose Postoperative radiation therapy (RT) is a common therapy used for patients with prostate cancer. Although clinical trials have established the safety and efficacy of hypofractionation as a primary therapy, there are limited data in a postoperative setting. We conducted a prospective trial to evaluate the safety and feasibility of postoperative hypofractionated RT to the prostate bed. Methods and Materials In this phase 2 trial, patients submitted to radical prostatectomy were treated with hypofractionated RT to the prostate bed (adjuvant or salvage). The prescribed dose was 51 Gy in 15 fractions (3.4 Gy per fraction), using intensity modulated and image guided radiation therapy techniques. The primary endpoint was the rate of acute genitourinary (GU) grade ≥2 toxicity. Secondary endpoints included acute gastrointestinal (GI) and late GU/GI toxicities, biochemical failure-free survival (BFFS), metastasis-free survival, cancer-specific survival, overall survival, and health-related quality of life. Results Of 64 enrolled patients, 61 received radiation therapy (57 salvage and 4 adjuvant radiation therapy). After a median follow-up of 16 months, 11.5% of patients experienced acute grade ≥2 GU symptoms and 13.1% experienced acute grade ≥2 GI symptoms. The late grade ≥2 GU toxicity rate was 8.2%, and 1 patient (1.6%) developed both acute and late grade 3 GU toxicity. The late grade ≥2 GI toxicity rate was 11.5%, and no grade 3 GI adverse events were reported. The short follow-up limits our ability to perform a robust oncologic endpoint assessment; however, the 2-year BFFS, use of subsequent salvage therapy, and the development of metastasis were 95.1%, 0%, and 0%, respectively. Conclusions Hypofractionated RT to the prostate bed in 15 treatments was safe, with an acceptable GU and GI toxicity profile. Further study in large, randomized trials is warranted. Postoperative radiation therapy (RT) is a common therapy used for patients with prostate cancer. Although clinical trials have established the safety and efficacy of hypofractionation as a primary therapy, there are limited data in a postoperative setting. We conducted a prospective trial to evaluate the safety and feasibility of postoperative hypofractionated RT to the prostate bed. In this phase 2 trial, patients submitted to radical prostatectomy were treated with hypofractionated RT to the prostate bed (adjuvant or salvage). The prescribed dose was 51 Gy in 15 fractions (3.4 Gy per fraction), using intensity modulated and image guided radiation therapy techniques. The primary endpoint was the rate of acute genitourinary (GU) grade ≥2 toxicity. Secondary endpoints included acute gastrointestinal (GI) and late GU/GI toxicities, biochemical failure-free survival (BFFS), metastasis-free survival, cancer-specific survival, overall survival, and health-related quality of life. Of 64 enrolled patients, 61 received radiation therapy (57 salvage and 4 adjuvant radiation therapy). After a median follow-up of 16 months, 11.5% of patients experienced acute grade ≥2 GU symptoms and 13.1% experienced acute grade ≥2 GI symptoms. The late grade ≥2 GU toxicity rate was 8.2%, and 1 patient (1.6%) developed both acute and late grade 3 GU toxicity. The late grade ≥2 GI toxicity rate was 11.5%, and no grade 3 GI adverse events were reported. The short follow-up limits our ability to perform a robust oncologic endpoint assessment; however, the 2-year BFFS, use of subsequent salvage therapy, and the development of metastasis were 95.1%, 0%, and 0%, respectively. Hypofractionated RT to the prostate bed in 15 treatments was safe, with an acceptable GU and GI toxicity profile. Further study in large, randomized trials is warranted." @default.
• W3112739539 created "2020-12-21" @default.
• W3112739539 creator A5000446823 @default.
• W3112739539 creator A5016682199 @default.
• W3112739539 creator A5019922405 @default.
• W3112739539 creator A5024195533 @default.
• W3112739539 creator A5054504055 @default.
• W3112739539 creator A5071742467 @default.
• W3112739539 creator A5086214975 @default.
• W3112739539 date "2021-04-01" @default.
• W3112739539 modified "2023-10-11" @default.
• W3112739539 title "Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial" @default.
• W3112739539 cites W1980601718 @default.
• W3112739539 cites W1988275108 @default.
• W3112739539 cites W1988587438 @default.
• W3112739539 cites W2036220888 @default.
• W3112739539 cites W2043945205 @default.
• W3112739539 cites W2127755970 @default.
• W3112739539 cites W2151660174 @default.
• W3112739539 cites W2278230463 @default.
• W3112739539 cites W2587523334 @default.
• W3112739539 cites W2589329045 @default.
• W3112739539 cites W2720170400 @default.
• W3112739539 cites W2770633848 @default.
• W3112739539 cites W2772136091 @default.
• W3112739539 cites W2897539375 @default.
• W3112739539 cites W2908398040 @default.
• W3112739539 cites W2912265329 @default.
• W3112739539 cites W2945219593 @default.
• W3112739539 cites W2958995476 @default.
• W3112739539 cites W2981757696 @default.
• W3112739539 cites W3087977689 @default.
• W3112739539 cites W3088103374 @default.
• W3112739539 cites W3088359655 @default.
• W3112739539 cites W3088633614 @default.
• W3112739539 cites W4236149208 @default.
• W3112739539 doi "https://doi.org/10.1016/j.ijrobp.2020.12.020" @default.
• W3112739539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33346091" @default.
• W3112739539 hasPublicationYear "2021" @default.
• W3112739539 type Work @default.
• W3112739539 sameAs 3112739539 @default.
• W3112739539 citedByCount "13" @default.
• W3112739539 countsByYear W31127395392021 @default.
• W3112739539 countsByYear W31127395392022 @default.
• W3112739539 countsByYear W31127395392023 @default.
• W3112739539 crossrefType "journal-article" @default.
• W3112739539 hasAuthorship W3112739539A5000446823 @default.
• W3112739539 hasAuthorship W3112739539A5016682199 @default.
• W3112739539 hasAuthorship W3112739539A5019922405 @default.
• W3112739539 hasAuthorship W3112739539A5024195533 @default.
• W3112739539 hasAuthorship W3112739539A5054504055 @default.
• W3112739539 hasAuthorship W3112739539A5071742467 @default.
• W3112739539 hasAuthorship W3112739539A5086214975 @default.
• W3112739539 hasConcept C116263406 @default.
• W3112739539 hasConcept C121608353 @default.
• W3112739539 hasConcept C126322002 @default.
• W3112739539 hasConcept C126894567 @default.
• W3112739539 hasConcept C133507102 @default.
• W3112739539 hasConcept C141071460 @default.
• W3112739539 hasConcept C143998085 @default.
• W3112739539 hasConcept C155806632 @default.
• W3112739539 hasConcept C197934379 @default.
• W3112739539 hasConcept C203092338 @default.
• W3112739539 hasConcept C2776694085 @default.
• W3112739539 hasConcept C2779466945 @default.
• W3112739539 hasConcept C2780192828 @default.
• W3112739539 hasConcept C2780775027 @default.
• W3112739539 hasConcept C29730261 @default.
• W3112739539 hasConcept C509974204 @default.
• W3112739539 hasConcept C535046627 @default.
• W3112739539 hasConcept C71924100 @default.
• W3112739539 hasConceptScore W3112739539C116263406 @default.
• W3112739539 hasConceptScore W3112739539C121608353 @default.
• W3112739539 hasConceptScore W3112739539C126322002 @default.
• W3112739539 hasConceptScore W3112739539C126894567 @default.
• W3112739539 hasConceptScore W3112739539C133507102 @default.
• W3112739539 hasConceptScore W3112739539C141071460 @default.
• W3112739539 hasConceptScore W3112739539C143998085 @default.
• W3112739539 hasConceptScore W3112739539C155806632 @default.
• W3112739539 hasConceptScore W3112739539C197934379 @default.
• W3112739539 hasConceptScore W3112739539C203092338 @default.
• W3112739539 hasConceptScore W3112739539C2776694085 @default.
• W3112739539 hasConceptScore W3112739539C2779466945 @default.
• W3112739539 hasConceptScore W3112739539C2780192828 @default.
• W3112739539 hasConceptScore W3112739539C2780775027 @default.
• W3112739539 hasConceptScore W3112739539C29730261 @default.
• W3112739539 hasConceptScore W3112739539C509974204 @default.
• W3112739539 hasConceptScore W3112739539C535046627 @default.
• W3112739539 hasConceptScore W3112739539C71924100 @default.
• W3112739539 hasIssue "5" @default.
• W3112739539 hasLocation W31127395391 @default.
• W3112739539 hasOpenAccess W3112739539 @default.
• W3112739539 hasPrimaryLocation W31127395391 @default.
• W3112739539 hasRelatedWork W1995051622 @default.
• W3112739539 hasRelatedWork W2011157603 @default.
• W3112739539 hasRelatedWork W2037499037 @default.
• W3112739539 hasRelatedWork W2116952544 @default.
• W3112739539 hasRelatedWork W2336846606 @default.

• next